Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer

Seminars in Cancer Biology

Volumn 46, Issue , 2017, Pages 146-157

  Pandima Devi, Kasi ^a   Rajavel, Tamilselvam ^a   Daglia, Maria ^b   Nabavi, Seyed Fazel ^c   Bishayee, Anupam ^d   Nabavi, Seyed Mohammad ^c  

^a ALAGAPPA UNIVERSITY   (India)

^b UNIVERSITY OF PAVIA   (Italy)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Larkin Health Science Institute   (United States)

Author keywords

Cancer; MiRNA; OncomiR; Polyphenols; Tumor suppressor miRNA

Indexed keywords

CURCUMIN; EPIGALLOCATECHIN GALLATE; GENISTEIN; MICRORNA; POLYPHENOL; QUERCETIN; RESVERATROL; TURMERIC; CATECHIN; STILBENE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CARCINOGENESIS; DRUG STRUCTURE; DRUG TARGETING; EPIGENETICS; GRAPE; HUMAN; MALIGNANT NEOPLASM; MOLECULAR PATHOLOGY; NONHUMAN; REVIEW; SOYBEAN; VICIA FABA; ANALOGS AND DERIVATIVES; DIET THERAPY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

CATECHIN; CURCUMIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; MICRORNAS; NEOPLASMS; POLYPHENOLS; SIGNAL TRANSDUCTION; STILBENES;

EID: 85011977686     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2017.02.001     Document Type: Review

References (159)

1. Blackadar, C.B., Historical review of the causes of cancer. World J. Clin. Oncol., 7, 2016, 54.
2. Colditz, G.A., Hunter, D.J., Cancer Prevention: The Causes and Prevention of Cancer. 2006, Springer Science & Business Media.
3. Verma, M., Srivastava, S., Molecular signatures of infectious agents in human cancer. Dis. Markers., 17, 2001, 121.
4. Moore, P.S., Chang, Y., Why do viruses cause cancer: highlights of the first century of human tumour virology. Nat. Rev. Cancer. 10 (2010), 878–889.
5. Zhang, H., DNA Replication-Damage from Environmental Carcinogens. 2015, Springer.
6. Globocan, I., Cancer Incidence and Mortality Worldwide in 2008. 2008, International Agency for Research on Cancer, WHO, Lyon.
7. Stewart, B., Wild, C.P., World Cancer Report 2014., 2016, World.
8. Arnold, M., Leitzmann, M., Freisling, H., Bray, F., Romieu, I., Renehan, A., et al. Obesity and cancer: an update of the global impact. Cancer Epidemiol. 41 (2016), 8–15.
9. Bandera, E.V., Fay, S.H., Giovannucci, E., Leitzmann, M.F., Marklew, R., McTiernan, A., et al. The use and interpretation of anthropometric measures in cancer epidemiology: a perspective from the world cancer research fund international continuous update project. Int. J. Cancer 139 (2016), 2391–2397.
10. Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 (2008), 569–578.
11. Ghosh, S., Guria, S., Das, M., Alcohol as a risk factor for cancer burden: a review. Proc. Zool. Soc.: Springer, 2016, 32–37.
12. Shield, K.D., Soerjomataram, I., Rehm, J., Alcohol use and breast cancer: a critical review. Alcohol Clin. Exp. Res. 40 (2016), 1166–1181.
13. Tantamango-Bartley, Y., Knutsen, S.F., Knutsen, R., Jacobsen, B.K., Fan, J., Beeson, W.L., et al. Are strict vegetarians protected against prostate cancer?. Am. J. Clin Nutr. 103 (2016), 153–160.
14. Kamil, N., Kamil, S., Global cancer incidences, causes and future predictions for subcontinent region. Syst. Rev. Pharm. 6 (2015), 13–17.
15. Malloy, A.H., Carson, C., Oncogene Proteins: New Research. 2008, Nova Science Publishers.
16. Pylayeva-Gupta, Y., Grabocka, E., Bar-Sagi, D., RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11 (2011), 761–774.
17. Kouvaraki, M.A., Shapiro, S.E., Perrier, N.D., Cote, G.J., Gagel, R.F., Hoff, A.O., et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 (2005), 531–544.
18. Stracquadanio, G., Wang, X., Wallace, M.D., Grawenda, A.M., Zhang, P., Hewitt, J., et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat. Rev. Cancer 16 (2016), 251–265.
19. Maclaine, N.J., Hupp, T.R., The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY) 1 (2009), 490–502.
20. Li, X.-L., Zhou, J., Chen, Z.-R., Chng, W.-J., P53 mutations in colorectal cancer—molecular pathogenesis and pharmacological reactivation. World J. Gastroenterol. 21 (2015), 84–93.
21. Deininger, P., Genetic instability in cancer: caretaker and gatekeeper genes. Ochsner J. 1 (1999), 206–209.
22. Pillai, R.S., MicroRNA function: multiple mechanisms for a tiny RNA. RNA 11 (2005), 1753–1761.
23. Lee, R.C., Feinbaum, R.L., Ambros, V., The, C., elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
24. Wightman, B., Ha, I., Ruvkun, G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75 (1993), 855–862.
25. Pasquinelli, A.E., Ruvkun, G., Control of developmental timing by microRNAs and their targets. Ann. Rev. Cell Dev. Biol. 18 (2002), 495–513.
26. Lee, Y., Kim, M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23 (2004), 4051–4060.
27. Lau, N.C., Lim, L.P., Weinstein, E.G., Bartel, D.P., An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294 (2001), 858–862.
28. Ghorai, A., Ghosh, U., miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. Front. Genet., 5, 2014, 100.
29. Denli, A.M., Tops, B.B., Plasterk, R.H., Ketting, R.F., Hannon, G.J., Processing of primary microRNAs by the Microprocessor complex. Nature 432 (2004), 231–235.
30. Terry, L.J., Shows, E.B., Wente, S.R., Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science 318 (2007), 1412–1416.
31. Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Natl. Acad. Sci. U. S. A. 101 (2004), 2999–3004.
32. Ferdin, J., Kunej, T., Calin, G.A., Non-coding RNAs: identification of cancer-associated microRNAs by gene profiling. Technol. Cancer Res.Treat. 9 (2010), 123–138.
33. Croce, C.M., Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10 (2009), 704–714.
34. Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 15524–15529.
35. Aqeilan, R., Calin, G., Croce C. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 17 (2010), 215–220.
36. Ferracin, M., Pedriali, M., Veronese, A., Zagatti, B., Gafà R., Magri, E., et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J. Pathol. 225 (2011), 43–53.
37. Mishra, P.J., Mishra, P.J., Banerjee, D., Bertino, J.R., MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 7 (2008), 853–858.
38. Chin, L.J., Ratner, E., Leng, S., Zhai, R., Nallur, S., Babar, I., et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non–small cell lung cancer risk. Cancer Res. 68 (2008), 8535–8540.
39. Mullany, L.E., Herrick, J.S., Wolff, R.K., Buas, M.F., Slattery, M.L., Impact of polymorphisms in microRNA biogenesis genes on colon cancer risk and microRNA expression levels: a population-based, case-control study. BMC Med Genom., 9, 2016, 1.
40. Qian, F., Feng, Y., Zheng, Y., Ogundiran, T.O., Ojengbede, O., Zheng, W., et al. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum. Genet. 135 (2016), 1145–1159.
41. Du, M., Lu, D., Wang, Q., Chu, H., Tong, N., Pan, X., et al. Genetic variations in microRNAs and the risk and survival of renal cell cancer. Carcinogenesis 35 (2014), 1629–1635.
42. Chuang, J.C., Jones, P.A., Epigenetics and microRNAs. Pediatr. Res. 61 (2007), 24R–29R.
43. Song, F.-J., Chen, K.-X., Single-nucleotide polymorphisms among microRNA: big effects on cancer. Chin. J. Cancer, 30, 2011, 381.
44. Nadal, E., Chen, G., Gallegos, M., Lin, L., Ferrer-Torres, D., Truini, A., et al. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin. Cancer Res. 19 (2013), 6842–6852.
45. Lujambio, A., Calin, G.A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. 105 (2008), 13556–13561.
46. Bandres, E., Agirre, X., Bitarte, N., Ramirez, N., Zarate, R., Roman-Gomez, J., et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 125 (2009), 2737–2743.
47. Zu, L., Xue, Y., Wang, J., Fu, Y., Wang, X., Xiao, G., et al. The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis. Carcinogenesis 37 (2016), 333–343.
48. Jiang, L., Yu, L., Zhang, X., Lei, F., Wang, L., Liu, X., et al. miR-892b silencing activates NF-κB and promotes aggressiveness in breast cancer. Cancer Res. 76 (2016), 1101–1111.
49. Sawan, C., Herceg, Z., Histone modifications and cancer. Adv. Genet. 70 (2010), 57–85.
50. Swierczynski, S., Klieser, E., Illig, R., Alinger-Scharinger, B., Kiesslich, T., Neureiter, D., Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Exp. Opin. Biol. Ther. 15 (2015), 651–664.
51. Wang, S., Li, H., Wang, J., Wang, D., Yao, A., Li, Q., Prognostic and biological significance of microRNA-127 expression in human breast cancer. Dis. Markers, 2014, 2014.
52. Cisneros-Soberanis, F., Andonegui, M.A., Herrera LA. miR-125b. SpringerPlus 5 (2016), 1–7.
53. Zhang, B., Pan, X., Cobb, G.P., Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302 (2007), 1–12.
54. Yuan, K., Lian, Z., Sun, B., Clayton, M.M., Ng, I.O., Feitelson, M.A., Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One, 7, 2012, e35331.
55. Zheng, B., Liang, L., Wang, C., Huang, S., Cao, X., Zha, R., et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Oncol. Targets Ther. 17 (2011), 7574–7583.
56. Yan, B., Guo, Q., Fu, F., Wang, Z., Yin, Z., Wei, Y., et al. The role of miR-29b in cancer: regulation, function, and signaling. Oncol. Targets Ther. 8 (2015), 539–548.
57. Jiang, H., Zhang, G., Wu, J.-H., Jiang, C.-P., Diverse roles of miR-29 in cancer (review). Oncol. Rep. 31 (2014), 1509–1516.
58. Mogilyansky, E., Rigoutsos, I., The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 20 (2013), 1603–1614.
59. Ventura, A., Young, A.G., Winslow, M.M., Lintault, L., Meissner, A., Erkeland, S.J., et al. Targeted deletion reveals essential and overlapping functions of the miR-17∼ 92 family of miRNA clusters. Cell 132 (2008), 875–886.
60. Zhang, B.G., Li, J.F., Yu, B.Q., Zhu, Z.G., Liu, B.Y., Yan M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol. Rep. 27 (2012), 1019–1026.
61. Jin, X.L., Sun, Q.S., Liu, F., Yang, H.W., Liu, M., Liu, H.X., et al. microRNA 21-mediated suppression of sprouty1 by Pokemon affects liver cancer cell growth and proliferation. J. Cell. Biochem. 114 (2013), 1625–1633.
62. Wang, Y.Y., Sun, G., Luo, H., Wang, X.F., Lan, F.M., Yue, X., et al. MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth. CNS Neurosci. Ther. 18 (2012), 722–728.
63. Mandal, C.C., Ghosh-Choudhury, T., Dey, N., Choudhury, G.G., Ghosh-Choudhury N. miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. Carcinogenesis, 2012, 2016, bgs198.
64. Yang, S-m., Huang, C., Li, X-f., Yu, M-z., He, Y., Li, J., miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 306 (2013), 162–168.
65. Liu, Z.-L., Wang, H., Liu, J., Wang, Z.-X., MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo-or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol. Cell. Biochem. 372 (2013), 35–45.
66. Xiong, B., Cheng, Y., Ma, L., Zhang, C., MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int. J. Oncol. 42 (2013), 219–228.
67. Zaman, M.S., Shahryari, V., Deng, G., Thamminana, S., Saini, S., Majid, S., et al. Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One, 7, 2012, e31060.
68. Gabriely, G., Wurdinger, T., Kesari, S., Esau, C.C., Burchard, J., Linsley, P.S., et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 28 (2008), 5369–5380.
69. Jung, H.M., Phillips, B.L., Patel, R.S., Cohen, D.M., Jakymiw, A., Kong, W.W., et al. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer. J. Biol. Chem. 287 (2012), 29261–29272.
70. Liu, C., Yu, J., Yu, S., Lavker, R.M., Cai, L., Liu, W., et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J. Hepatol. 53 (2010), 98–107.
71. Roush, S., Slack, F.J., The let-7 family of microRNAs. Trends Cell Biol. 18 (2008), 505–516.
72. Boyerinas, B., Park, S.-M., Hau, A., Murmann, A.E., Peter, M.E., The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 17 (2010), F19–F36.
73. Guan, J., Guo, S., Liu, M., Let-7 family miRNAs represent potential broad-Spectrum therapeutic molecules for human cancer. J. Genet. Syndrome Gene Ther., 6, 2015, 1.
74. Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. RAS is regulated by the let-7 microRNA family. Cell 120 (2005), 635–647.
75. Mayr, C., Hemann, M.T., Bartel, D.P., Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315 (2007), 1576–1579.
76. Fernández-Medarde, A., Santos, E., Ras in cancer and developmental diseases. Genes Cancer 2 (2011), 344–358.
77. Lamoral-Theys, D., Pottier, L., Dufrasne, F., Neve, J., Dubois, J., Kornienko, A., et al. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr. Med. Chem. 17 (2010), 812–825.
78. Kim, H.-S., Quon, M.J., Kim, J-a., New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Red. Biol. 2 (2014), 187–195.
79. Rodríguez, M., Estrela, J., Ortega, Á., Natural polyphenols and apoptosis induction in cancer therapy. J. Carcinog Mutag S, 6, 2013.
80. Block, K.I., Gyllenhaal, C., Lowe, L., Amedei, A., Amin, A.R., Amin, A., et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol. 35 (2015), S276–S304.
81. Devi, K.P., Rajavel, T., Nabavi, S.F., Setzer, W.N., Ahmadi, A., Mansouri, K., et al. Hesperidin: a promising anticancer agent from nature. Ind. Crops Prod. 76 (2015), 582–589.
82. Russo, M., Russo, G.L., Daglia, M., Kasi, P.D., Ravi, S., Nabavi, S.F., et al. Understanding genistein in cancer: the good and the bad effects: a review. Food Chem. 196 (2016), 589–600.
83. Milenkovic, D., Jude, B., Morand, C., miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med. 64 (2013), 40–51.
84. Shankar, E., Kanwal, R., Candamo, M., Gupta, S., Dietary phytochemicals as epigenetic modifiers in cancer: promise and challenges. Semin. Cancer Biol. 40–41 (2016), 82–99.
85. Curti, V., Capelli, E., Boschi, F., Nabavi, S.F., Bongiorno, A.I., Habtemariam, S., et al. Modulation of human miR-17-3p expression by methyl 3-O-methyl gallate as explanation of its in vivo protective activities. Mol. Nutr. Food Res. 58 (2014), 1776–1784.
86. Mudduluru, G., George-William, J.N., Muppala, S., Asangani, I.A., Kumarswamy, R., Nelson, L.D., et al. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. 31 (2011), 185–197.
87. Srivastava, S.K., Arora, S., Averett, C., Singh, S., Singh, A.P., Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance. BioMed Res. Int., 2015, 2015.
88. Parasramka, M.A., Ho, E., Williams, D.E., Dashwood, R.H., MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol. Carcinogen 51 (2012), 213–230.
89. Sengupta, S., Bishayee, A., MicroRNAs in cancer therapy: from bench to bedside. Curr. Cancer Ther. Rev. 6 (2010), 157–162.
90. Nabavi, S.F., Daglia, M., Moghaddam, A.H., Habtemariam, S., Nabavi, S.M., Curcumin and liver disease: from chemistry to medicine. Compr. Rev. Food Sci. Food Saf. 13 (2014), 62–77.
91. Roy, S., Yu, Y., Padhye, S.B., Sarkar, F.H., Majumdar, A.P., Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One, 8, 2013, e68543.
92. Zhang, W., Bai, W., MiR-21 suppresses the anticancer activities of curcumin by targeting PTEN gene in human non-small cell lung cancer A549 cells. Clin. Transl. Oncol. 16 (2014), 708–713.
93. Li, X., Xie, W., Xie, C., Huang, C., Zhu, J., Liang, Z., et al. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 Breast cancer cell proliferation. Phytother. Res. 28 (2014), 1553–1560.
94. Mavrakis, K.J., Wolfe, A.L., Oricchio, E., Palomero, T., De Keersmaecker, K., McJunkin, K., et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 12 (2010), 372–379.
95. Yang, C.H., Yue, J., Sims, M., Pfeffer, L.M., The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PLoS One, 8, 2013, e71130.
96. Zhang, J., Zhang, T., Ti, X., Shi, J., Wu, C., Ren, X., et al. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem. Biophysic. Res. Commun. 399 (2010), 1–6.
97. Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prevent. Res. 2 (2009), 409–418.
98. Varoni, E.M., Faro, A.F.L., Sharifi-Rad, J., Iriti, M., Anticancer molecular mechanisms of resveratrol. Front. Nutr., 3, 2016.
99. Sheth, S., Jajoo, S., Kaur, T., Mukherjea, D., Sheehan, K., Rybak, L.P., et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One, 7, 2012, e51655.
100. Dhar, S., Hicks, C., Levenson, A.S., Resveratrol and prostate cancer: promising role for microRNAs. Mol. Nutr. Food Res. 55 (2011), 1219–1229.
101. Tili, E., Michaille, J.-J., Adair, B., Alder, H., Limagne, E., Taccioli, C., et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 31 (2010), 1561–1566.
102. Hirata, H., Ueno, K., Nakajima, K., Tabatabai, Z., Hinoda, Y., Ishii, N., et al. Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br. J. Cancer 108 (2013), 2070–2078.
103. Qin, J., Chen, J.X., Zhu, Z., Teng, J.A., Genistein inhibits human colorectal cancer growth and suppresses miR-95, Akt and SGK1. Cell. Physiol. Biochem. 35 (2015), 2069–2077.
104. Nabavi, S.F., Russo, G.L., Daglia, M., Nabavi, S.M., Role of quercetin as an alternative for obesity treatment: you are what you eat!. Food Chem. 179 (2015), 305–310.
105. Khan, F., Niaz, K., Maqbool, F., Ismail Hassan, F., Abdollahi, M., Nagulapalli Venkata, K.C., et al. Molecular targets underlying the anticancer effects of quercetin: an update. Nutrients, 8, 2016, 529.
106. Murakami, A., Ashida, H., Terao, J., Multitargeted cancer prevention by quercetin. Cancer Lett. 269 (2008), 315–325.
107. Pratheeshkumar, P., Son, Y.-O., Divya, S.P., Wang, L., Turcios, L., Roy, R.V., et al. Quercetin inhibits Cr (VI)-induced malignant cell transformation by targeting miR-21-PDCD4 signaling pathway. Oncotarget, 2016, 2016.
108. Yamada, S., Tsukamoto, S., Huang, Y., Makio, A., Kumazoe, M., Yamashita, S., et al. Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. Sci. Rep., 6, 2016.
109. Appari, M., Babu, K.R., Kaczorowski, A., Gross, W., Herr, I., Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. Int. J. Oncol. 45 (2014), 1391–1400.
110. Zhong, Z., Dong, Z., Yang, L., Chen, X., Gong, Z., Inhibition of proliferation of human lung cancer cells by green tea catechins is mediated by upregulation of let-7. Exp. Ther. Med. 4 (2012), 267–272.
111. Nwaeburu, C.C., Bauer, N., Zhao, Z., Abukiwan, A., Gladkich, J., Benner, A., et al. Up-regulation of microRNA Let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl. Oncotarget 7 (2016), 58367–58380.
112. Zhu, K., Wang, W., Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1. Tumor Biol. 37 (2016), 4373–4382.
113. Bhaumik, D., Scott, G., Schokrpur, S., Patil, C., Campisi, J., Benz, C., Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27 (2008), 5643–5647.
114. Tao, S.-f., He, H.-f., Chen, Q., Quercetin inhibits proliferation and invasion acts by up-regulating miR-146a in human breast cancer cells. Mol. Cell. Biochem. 402 (2015), 93–100.
115. Su, Y., Ni, Z., Wang, G., Cui, J., Wei, C., Wang, J., et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int. Immunopharmacol. 13 (2012), 468–475.
116. Tatarano, S., Chiyomaru, T., Kawakami, K., Enokida, H., Yoshino, H., Hidaka, H., et al. Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. Int. J. Oncol. 40 (2012), 951–959.
117. Chiyomaru, T., Yamamura, S., Fukuhara, S., Hidaka, H., Majid, S., Saini, S., et al. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS One, 8, 2013, e58929.
118. Mitash, N., Agnihotri, S., Mittal, B., Tiwari, S., Mandhani, A., Molecular cystoscopy: micro-RNAs could be a marker for identifying genotypic changes for transitional cell carcinoma of the urinary bladder. Indian J. Urol., 32, 2016, 149.
119. Güllü G., Peker, I., Haholu, A., Eren, F., Küçükodaci, Z., Güleç B., et al. Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5. Genet. Mol. Biol. 38 (2015), 21–29.
120. Zhang, B., Zhao, R., He, Y., Fu, X., Fu, L., Zhu, Z., et al. Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget, 7, 2016, 5702.
121. Deng, X., Wu, B., Xiao, K., Kang, J., Xie, J., Zhang, X., et al. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell. Physiol. Biochem. 35 (2015), 71–82.
122. Liu, Y., Xu, J., Jiang, M., Ni, L., Chen, Y., Ling, Y., Association between functional PSMD10 Rs111638916 variant regulated by MiR-505 and gastric cancer risk in a Chinese population. Cell. Physiol. Biochem. 37 (2015), 1010–1017.
123. Lan, G., Yang, L., Xie, X., Peng, L., Wang, Y., MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer. Arch Med Sci. 11 (2015), 561–569.
124. Hu, N., Wang, C., Clifford, R.J., Yang, H.H., Su, H., Wang, L., et al. Integrative genomics analysis of genes with biallelic loss and its relation to the expression of mRNA and micro-RNA in esophageal squamous cell carcinoma. BMC genomics., 16, 2015, 1.
125. Kaukoniemi, K.M., Rauhala, H.E., Scaravilli, M., Latonen, L., Annala, M., Vessella, R.L., et al. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 4 (2015), 1417–1425.
126. Chung, E.H., Yang, H., Xing, H., Carroll, R.S., Johnson MD. miR-505 downregulates 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 4 to promote cell death in glioblastoma. Cancer Transl. Med., 1, 2015, 158.
127. Akbari, A., Ghahremani, M.H., Mobini, G.R., Abastabar, M., Akhtari, J., Bolhassani, M., et al. Down-regulation of miR-135b in colon adenocarcinoma induced by a TGF-β receptor I kinase inhibitor (SD-208). Iranian J. Basic Med. Sci., 18, 2015, 856.
128. Troppan, K., Wenzl, K., Pichler, M., Pursche, B., Schwarzenbacher, D., Feichtinger, J., et al. miR-199a and miR-497 are associated with better overall survival due to increased chemosensitivity in diffuse large B-cell lymphoma patients. Int. J. Mol. Sci. 16 (2015), 18077–18095.
129. Tuomarila, M., Luostari, K., Soini, Y., Kataja, V., Kosma, V.-M., Mannermaa, A., Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer. PLoS One, 9, 2014, e109508.
130. Sun, S., Zhang, G., Wu, Z., Shi, W., Yang, B., MicroR.N.A-302a, Li Y., Functions as a putative tumor suppressor in colon cancer by targeting akt. PLoS One, 9, 2014, e115980.
131. Zhang, G.-M., Bao, C.-Y., Wan, F.-N., Cao, D.-L., Qin, X.-J., Zhang, H.-L., et al. MicroRNA-302a suppresses tumor cell proliferation by inhibiting AKT in prostate cancer. PLoS One, 10, 2015, e0124410.
132. Yamamoto, K., Ito, S., Hanafusa, H., Shimizu, K., Ouchida, M., Uncovering direct targets of miR-19a involved in lung cancer progression. PLoS One, 10, 2015, e0137887.
133. Schwickert, A., Weghake, E., Brüggemann, K., Engbers, A., Brinkmann, B.F., Kemper, B., et al. microRNA miR-142-3p inhibits Breast cancer cell invasiveness by synchronous targeting of WASL, integrin alpha V, and additional cytoskeletal elements. PLoS One, 10, 2015, e0143993.
134. Yu, Z., Zhang, W., Deng, F., MicroRNA-577 inhibits gastric cancer growth by targeting E2F transcription factor 3. Oncol. Lett. 10 (2015), 1447–1452.
135. Stope, M.B., Hettenbach, D., Kaul, A., Paditz, M., Diesing, K., Burchardt, M., et al. The tumor suppressor microRNA-1 exhibits restricted inhibition of proliferation of ovarian cancer cells. Anticancer Res. 36 (2016), 3329–3334.
136. Mignacca, L., Saint-Germain, E., Benoit, A., Bourdeau, V., Moro, A., Ferbeyre, G., Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine 82 (2016), 80–86.
137. Cheng, S., Xu, Y., Shi, Z., Lin, Y., Hoang, C.D., Zhang, X., Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells. Thorac. Cancer, 2016.
138. Cui, H., Mu, Y., Yu, L., Xi, Y.-g., Matthiesen, R., Su, X., et al. Methylation of the miR-126 gene associated with glioma progression. Fam. Cancer 15 (2016), 317–324.
139. Wang, Y., Xu, P., Yao, J., Yang, R., Shi, Z., Zhu, X., et al. MicroRNA-216b is down-Regulated in human gastric adenocarcinoma and inhibits proliferation and cell cycle progression by targeting oncogene HDAC8. Target. Oncol. 11 (2016), 197–207.
140. Tian, F., Han, Y., Yan, X., Zhong, D., Yang, G., Lei, J., et al. Upregulation of microrna-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. Thorac. Cancer 7 (2016), 226–231.
141. Todorova, K., Metodiev, M.V., Metodieva, G., Zasheva, D., Mincheff, M., Hayrabedyan S. miR-204 is dysregulated in metastatic prostate cancer in vitro. Mol. Carcinogen 55 (2016), 131–147.
142. Che, L.-F., Shao, S.F., Wang, L.X., Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107. Exp. Ther. Med. 11 (2016), 503–509.
143. Jain, M.V., Shareef, A., Likus, W., Cieślar-Pobuda, A., Ghavami, S., Łos, M.J., Inhibition of miR301 enhances Akt-mediated cell proliferation by accumulation of PTEN in nucleus and its effects on cell-cycle regulatory proteins. Oncotarget 7 (2016), 20953–20965.
144. Toden, S., Tran, H.-M., Tovar-Camargo, O.A., Okugawa, Y., Goel, A., Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget 7 (2016), 16158–16171.
145. Zhou, H., Manthey, J., Lioutikova, E., Yang, W., Yoshigoe, K., Yang, M.Q., et al. The up-regulation of Myb may help mediate EGCG inhibition effect on mouse lung adenocarcinoma. Hum. Genomics, 10, 2016, 19.
146. Dhar, S., Kumar, A., Rimando, A.M., Zhang, X., Levenson, A.S., Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget 6 (2015), 27214–27226.
147. Liu, P., Liang, H., Xia, Q., Li, P., Kong, H., Lei, P., et al. Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression. Clin. Transl. Oncol. 15 (2013), 741–746.
148. Sibbesen, N.A., Kopp, K.L., Litvinov, I.V., Jønson, L., Willerslev-Olsen, A., Fredholm, S., et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget, 6, 2015, 20555.
149. Wang, H., Bian, S., Yang, C.S., Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis, 2011, 2016, bgr218.
150. Chakrabarti, M., Klionsky, D.J., Ray, S.K., miR-30e blocks autophagy and acts synergistically with proanthocyanidin for inhibition of AVEN and BIRC6 to increase apoptosis in glioblastoma stem cells and glioblastoma SNB19Cells. PLoS One, 11, 2016, e0158537.
151. Yang, S., Li, W., Sun, H., Wu, B., Ji, F., Sun, T., et al. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo. BMC Cancer, 15, 2015, 1.
152. Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J.M., et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70 (2010), 3606–3617.
153. Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A.S., et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 72 (2012), 335–345.
154. Roy, S., Levi, E., Majumdar, A.P., Sarkar, F.H., Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J. Hematol. Oncol., 5, 2012, 1.
155. Ali, S., Ahmad, A., Aboukameel, A., Bao, B., Padhye, S., Philip, P.A., et al. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett. 319 (2012), 173–181.
156. Bao, B., Ali, S., Kong, D., Sarkar, S.H., Wang, Z., Banerjee, S., et al. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One, 6, 2011, e17850.
157. Bao, B., Ali, S., Ahmad, A., Azmi, A.S., Li, Y., Banerjee, S., et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One, 7, 2012, e50165.
158. Yallapu, M.M., Khan, S., Maher, D.M., Ebeling, M.C., Sundram, V., Chauhan, N., et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35 (2014), 8635–8648.
159. Yang, S.-F., Lee, W.-J., Tan, P., Tang, C.-H., Hsiao, M., Hsieh, F.-K., et al. Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas. Oncotarget 6 (2015), 2736–2753.